Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Provenge Outcomes Data "Moderately" Strong For Labeled Use; Off-Label Insufficient, AHRQ Tech Assessment Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Clinical research demonstrating positive health outcomes from Dendreon's prostate cancer vaccine Provenge is "moderately" strong, the Agency for Healthcare Research and Quality concludes in a draft technology assessment prepared for the upcoming meeting of the Medicare Evidence Development and Coverage Advisory Committee.

You may also be interested in...



Provenge Coverage With Data Collection Suggested By MEDCAC Members

The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.

Provenge Coverage With Data Collection Suggested By MEDCAC Members

The Centers for Medicare and Medicaid Services got a number of suggestions about linking Medicare coverage with data collection for Dendreon’s therapeutic prostate cancer vaccine Provenge at the Medicare Evidence Development and Coverage Advisory Committee’s Nov. 17 meeting.

Is Provenge "Reasonable And Necessary"? CMS Analysis For Medicare Coverage Seeks To Find Out

The Centers for Medicare and Medicaid Services may consider setting formal parameters around Medicare coverage for Dendreon's ground-breaking prostate cancer vaccine Provenge next year.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS071433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel